Ascendis Pharma A/S
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Ascendis Pharma A/S has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Ascendis Pharma A/S filed with the SEC
Ascendis Pharma Reports Second Quarter 2026 Financial Results
EX-99.1 to Form 6-K
Ascendis Pharma Reports First Quarter 2026 Financial Results
EX-99.1 to Form 6-K
Notice to Convene Annual General Meeting 2026
EX-99.1 to Form 6-K
Central Business Registration No. 29 91 87 91
EX-99.2 to Form 6-K
Corporate Responsibility & P|ESG Report 2025 www.ascendispharma.com
EX-99.3 to Form 6-K
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
EX-99.1 to Form 6-K
Ascendis Pharma Reports Third Quarter 2025 Financial Results
EX-99.1 to Form 6-K
Ascendis Pharma Reports Second Quarter 2025 Financial Results
EX-99.1 to Form 6-K
Ascendis Pharma Reports First Quarter 2025 Financial Results
EX-99.1 to Form 6-K
Notice to convene Annual General Meeting 2025
EX-99.1 to Form 6-K
Central Business Registration No. 29 91 87 91
EX-99.2 to Form 6-K
Patients|Environmental, Social and Governance Report (P|ESG) Content
EX-99.3 to Form 6-K
Ascendis Pharma Reports Fourth Quarter and Full Year 2024
EX-99.1 to Form 6-K
Ascendis Pharma Reports Third Quarter 2024 Financial Results
EX-99.1 to Form 6-K
Ascendis Pharma Reports Second Quarter 2024 Financial Results
EX-99.1 to Form 6-K
Ascendis Pharma Reports First Quarter 2024 Financial Results
EX-99.1 to Form 6-K
Notice to convene Annual General Meeting 2024
EX-99.1 to Form 6-K
Central Business Registration No. 29 91 87 91
EX-99.2 to Form 6-K
Sustainability & P|ESG Report 2023 www.ascendispharma.com
EX-99.3 to Form 6-K
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
EX-99.1 to Form 6-K
Ascendis Pharma A/S 42nd Annual J.P.
EX-99.1 to Form 6-K
Ascendis Pharma Reports Third Quarter 2023 Financial Results
EX-99.1 to Form 6-K
Ascendis Pharma Reports Second Quarter 2023 Financial Results
EX-99.1 to Form 6-K
Long-Term Efficacy and Safety of
EX-99.1 to Form 6-K
Ascendis Pharma A/S Oncology Program
EX-99.1 to Form 6-K
Notice to convene Annual General Meeting 2023
EX-99.1 to Form 6-K
Central Business Registration No. 29 91 87 91
EX-99.2 to Form 6-K